Skip to Content
UW Health SMPH
American Family Children's Hospital
William R. Schelman, MD, PhD close
William R. Schelman, MD, PhD

William R. Schelman, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Schelman is an assistant professor of medicine within the Hematology-Oncology section of the University of Wisconsin School of Medicine and Public Health. Dr. Schelman received his medical degree and PhD from the University of Illinois at Urbana-Champaign. He completed his internship and residency in internal medicine at UW. Prior to entering the clinical fellowship, Dr. Schelman did research under a T-32 training grant characterizing proteins expressed in hepatocellular carcinoma. He then completed his medical oncology fellowship at the UW Carbone Cancer Center. He is board certified in Internal Medicine. As an oncologist, his clinical practice and research interests are in gastrointestinal cancers, with a focus on liver tumors, and experimental therapeutics.


Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Other Locations

University Specialty Clinic (Mauston)
(608) 847-7355 |  Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

Languages Spoken

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Medical Oncology
Fellowship UW Carbone Cancer Center, Madison
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Illinois College of Medicine, Chicago, 2000


Dr. Schelman is part of the gastrointestinal Disease-Oriented Working Group, through which multiple clinical trials in GI tumors are helping to find better treatments for those with cancer. His research interest is to identify more specific molecular markers and therapeutic targets for the detection and treatment of liver and colon tumors and to use this information to shape drug development.

PubMed Articles
Deming DA Ninan J Bailey HH Kolesar JM Eickhoff J Reid JM Ames MM McGovern RM Alberti D Marnocha R Espinoza-Delgado I Wright J Wilding G Schelman WR . A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Apr;32(2):323-9
[PubMed ID: 24114123]
Schelman WR Mohammed TA Traynor AM Kolesar JM Marnocha RM Eickhoff J Keppen M Alberti DB Wilding G Takebe N Liu G . A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr;32(2):295-302
[PubMed ID: 23860642]
Bultman EM Brodsky EK Horng DE Irarrazaval P Schelman WR Block WF Reeder SB . Quantitative hepatic perfusion modeling using DCE-MRI with sequential breathholds. J Magn Reson Imaging. 2014 Apr;39(4):853-65
[PubMed ID: 24395144]
Paul Olson TJ Hadac JN Sievers CK Leystra AA Deming DA Zahm CD Albrecht DM Nomura A Nettekoven LA Plesh LK Clipson L Sullivan R Newton MA Schelman WR Halberg RB . Dynamic tumor growth patterns in a novel murine model of colorectal cancer. Cancer Prev Res (Phila). 2014 Jan;7(1):105-13
[PubMed ID: 24196829]
Schelman WR Traynor AM Holen KD Kolesar JM Attia S Hoang T Eickhoff J Jiang Z Alberti D Marnocha R Reid JM Ames MM McGovern RM Espinoza-Delgado I Wright JJ Wilding G Bailey HH . A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec;31(6):1539-46
[PubMed ID: 24114121]
Kolesar JM Traynor AM Holen KD Hoang T Seo S Kim K Alberti D Espinoza-Delgado I Wright JJ Wilding G Bailey HH Schelman WR . Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7
[PubMed ID: 23903894]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ . A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Brodsky EK Bultman EM Johnson KM Horng DE Schelman WR Block WF Reeder SB . High-spatial and high-temporal resolution dynamic contrast-enhanced perfusion imaging of the liver with time-resolved three-dimensional radial MRI. Magn Reson Med. 2013 Mar 20;
[PubMed ID: 23519837]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G . Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Fashoyin A Hartig G Schelman WR Ritter M Agni R Gopal DV Pfau PR Weiss JM . Aggressive adenocarcinoma of the cervical esophagus: importance of a multidisciplinary approach. Case Rep Gastrointest Med. 2012;2012:826246
[PubMed ID: 23304576]
Schelman WR Liu G Wilding G Morris T Phung D Dreicer R . A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs. 2011 Feb;29(1):118-25
[PubMed ID: 19763400]
Kolesar JM Sachidanandam K Schelman WR Eickhoff J Holen KD Traynor AM Alberti DB Thomas JP Chitambar CR Wilding G Antholine WE . Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011 Jan;2(1):119-123
[PubMed ID: 21373381]
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK . A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-43
[PubMed ID: 21632454]
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H . A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7
[PubMed ID: 21393344]
Choi BS Alberti DB Schelman WR Kolesar JM Thomas JP Marnocha R Eickhoff JC Ivy SP Wilding G Holen KD . The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80
[PubMed ID: 20127092]
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL . A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 Jul;9(3):157-61
[PubMed ID: 20643620]
Kolesar J Huang W Eickhoff J Hahn K Alberti D Attia S Schelman W Holen K Traynor A Ivy P Wilding G . Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86
[PubMed ID: 18941749]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G . Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
Schelman WR Morgan-Meadows S Marnocha R Lee F Eickhoff J Huang W Pomplun M Jiang Z Alberti D Kolesar JM Ivy P Wilding G Traynor AM . A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 May;63(6):1147-56
[PubMed ID: 19082825]
Schelman W Morgan-Meadows S Bailey H Holen K Thomas JP Eickhoff J Brandon H Oliver K Alberti D Wilding G . A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Sep;62(4):727-33
[PubMed ID: 18172649]